AstraZeneca PLC (AZN) wins appeals court ruling on Crestor patent
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
AstraZeneca (AZN) Receives Favorable Decision in Crestor Patent Appeal
December 14, 2012 1:22 PM ESTAstraZeneca (NYSE: AZN) announced that the Court of Appeals for the Federal Circuit has upheld the decision of the District Court, District of Delaware, finding that the substance patent protecting CRESTOR (rosuvastatin calcium) (RE37,314 the 314 patent) is valid and enforceable. The defendants may... More
